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Abstract: Loss of function of the urea cycle enzyme argininosuccinate lyase (ASL) is caused by mutations
in the ASL gene leading to ASL deficiency (ASLD). ASLD has a broad clinical spectrum ranging from
life-threatening severe neonatal to asymptomatic forms. Different levels of residual ASL activity probably
contribute to the phenotypic variability but reliable expression systems allowing clinically useful conclu-
sions are not yet available. In order to define the molecular characteristics underlying the phenotypic
variability, we investigated all ASL mutations that were hitherto identified in patients with late onset
or mild clinical and biochemical courses by ASL expression in human embryonic kidney 293 T cells. We
found residual activities >3% of ASL wild type (WT) in nine of 11 ASL mutations. Six ASL mutations
(p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu, and p.Arg379Cys) with residual ac-
tivities ฀16% of ASL WT showed no significant or less than twofold reduced Km values, but displayed
thermal instability. Computational structural analysis supported the biochemical findings by revealing
multiple effects including protein instability, disruption of ionic interactions and hydrogen bonds between
residues in the monomeric form of the protein, and disruption of contacts between adjacent monomeric
units in the ASL tetramer. These findings suggest that the clinical and biochemical course in variant
forms of ASLD is associated with relevant residual levels of ASL activity as well as instability of mutant
ASL proteins. Since about 30% of known ASLD genotypes are affected by mutations studied here, ASLD
should be considered as a candidate for chaperone treatment to improve mutant protein stability.
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Abstract Loss of function of the urea cycle enzyme
argininosuccinate lyase (ASL) is caused by mutations in the
ASL gene leading to ASL deficiency (ASLD). ASLD has a
broad clinical spectrum ranging from life-threatening severe
neonatal to asymptomatic forms. Different levels of residual
ASL activity probably contribute to the phenotypic variability
but reliable expression systems allowing clinically useful con-
clusions are not yet available. In order to define the molecular
characteristics underlying the phenotypic variability, we in-
vestigated all ASL mutations that were hitherto identified in
patients with late onset or mild clinical and biochemical
courses by ASL expression in human embryonic kidney
293 T cells. We found residual activities >3 % of ASL wild
type (WT) in nine of 11 ASL mutations. Six ASL mutations
(p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly,
p.Val335Leu, and p.Arg379Cys) with residual activities
≥16 % of ASLWTshowed no significant or less than twofold
reduced Km values, but displayed thermal instability. Compu-
tational structural analysis supported the biochemical findings
by revealing multiple effects including protein instability, dis-
ruption of ionic interactions and hydrogen bonds between
residues in the monomeric form of the protein, and disruption
of contacts between adjacent monomeric units in the ASL
tetramer. These findings suggest that the clinical and biochem-
ical course in variant forms of ASLD is associated with rele-
vant residual levels of ASL activity as well as instability of
mutant ASL proteins. Since about 30 % of known ASLD
genotypes are affected by mutations studied here, ASLD
should be considered as a candidate for chaperone treatment
to improve mutant protein stability.
Introduction
Argininosuccinate lyase deficiency (ASLD,MIM #207900) is
a rare autosomal-recessive urea cycle defect caused by muta-
tions in the ASL gene encoding argininosuccinate lyase (ASL,
EC 4.3.2.1, MIM *608310). ASL catalyzes the hydrolytic
cleavage of argininosuccinate into arginine and fumarate and
is, as part of the urea cycle, essential for ammonia detoxifica-
tion and L-arginine synthesis (Brusilow and Horwich 2001).
ASLD is considered the second most common urea cycle
disorder (UCD) with an estimated incidence of 1:70,000 live
births (Brusilow and Horwich 2001; Brusilow and Maestri
1996; Erez et al 2011a).
Biochemically, frequent findings in ASLD are
hyperammonemia, an unfortunately unspecific sign, and
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accumulation of argininosuccinic acid in tissues and body
fluids (hence the synonymous term argininosuccinic aciduria,
ASA), the latter being a specific and thus diagnostic biochem-
ical marker (Solitare et al 1969; Tomlinson and Westall 1960,
1964). Levels of argininosuccinic acid in blood or urine vary
between patients but there is no useful correlation between
this marker and the severity of disease.
Clinically, patients with ASLD show a continuum from
asymptomatic individuals over mild late onset forms to severe
neonatal onset presentations with fatal hyperammonemic en-
cephalopathy within the first few days of life (Erez et al
2011a). In contrast to most other UCDs, patients with ASLD
seem to be affected by intellectual disability independent from
the occurrence of hyperammonemic decompensations. In ad-
dition, for UCDs unusual and not fully understood complica-
tions of ASLD are the frequent findings of hepatic disease
(Mori et al 2002; Zimmermann et al 1986) and of arterial
hypertension (Brunetti-Pierri et al 2009) indicating to addi-
tional and possibly tissue-specific biological functions of
ASL (Erez et al 2011b).
The ASL gene is located on chromosome 7cen-q11.2 and
comprises 16 coding exons (NM_000048) (Linnebank et al
2002; O’Brien et al 1986; Todd et al 1989). The coding region
of 1392 base pairs encodes a polypeptide of 464 amino acids
(NP_000039), which forms as active enzyme a cytosolic
homotetramer with a subunit molecular weight of ∼52 kDa
(O’Brien and Barr 1981; Palekar and Mantagos 1981). ASL
is ubiquitously expressed in the human body with highest
levels in the liver. A sequence on chromosome 22 was previ-
ously considered as a pseudogene (Linnebank et al 2002;
O’Brien et al 1986) but later found to encode Ig-λ like mRNA
(Linnebank et al 2002). Recently, an ASL pseudogene, which
includes sequences from intron two to intron three, was identi-
fied upstream of the human ASL gene on chromosome 7
(Trevisson et al 2007). Mutations are spread almost all over
the ASL gene and have recently been reviewed (Balmer et al
2014). Several attempts have been made to accomplish a prog-
nostic marker and improve our understanding of the biochem-
ical and clinical variability of ASLD. Enzymatic assays in
erythrocytes (Mercimek-Mahmutoglu et al 2010; Tanaka et al
2002) or in cultured skin fibroblasts by direct (Tomlinson and
Westall 1964) or indirect ASLmeasurement (Jacoby et al 1972;
Kleijer et al 2002) have proven to be of some prognostic value
for selected patients but lacked predictive reliability. Neverthe-
less, the indirect ASL assay by analysis of 14C-citrulline incor-
poration in intact fibroblasts yielded sufficient sensitivity for
detection of residual activities in variant forms of ASLD
(Ficicioglu et al 2009; Kleijer et al 2002; Linnebank et al
2002) comprising patients with non-classical ASLD affected
by only mild clinical symptoms, slight biochemical abnormal-
ities, but no or only mild hyperammonemia.
In addition to measurements in patients’ samples, there are
some in vitro assays investigating naturally occurring ASL
mutations in bacterial (E. coli) (Engel et al 2012; Sampaleanu
et al 2001; Yu et al 2001), yeast (Barbosa et al 1991; Doimo
et al 2012; Trevisson et al 2009) and eukaryotic (COS1-cells)
(Walker et al 1990, 1997) expression systems. While identifi-
cation of severely affected ASL proteins was feasible in all of
these, there was overall no satisfying sensitivity for residual
ASL activities and hence the predictive value was limited.
In the present study, we use our recently established eu-
karyotic expression system in human embryonic kidney 293 T
cell lysates (Hu et al 2013) to investigate all naturally occur-
ring ASL mutations up until now identified in patients with a
variant biochemical or clinical phenotype in an attempt to
better understand the cause of the broad variation in ASLD
phenotypes. We found evidence for thermal instability as well
as low expression levels pointing towards a hampered stability
in these mutant ASL proteins, hereby contributing to our un-
derstanding of the underlying pathology in a part of ASLD.
Material and methods
Choice of ASL mutations
In this study, 13 known ASL sequence changes including the
severe mutat ions p.Gln286Arg (c .857A >G) and
p.Arg385Leu (c.1154G>T) as negative controls were investi-
gated together with WT ASL (Fig. 1). Of the total 13 muta-
tions, 11 (p.Arg12Gln (c.35G>A), p.Asp31Asn (c.91G>A),
p.Arg95Cys (c.283C>T), p.Ile100Thr (c.299 T>C),
p.Val178Met (c.532G>A), p.Glu189Gly (c.566A>G),
p.Arg193Trp (c.577C>T), p.Val335Leu (c.1003G>T),
p.Arg379Cys (c.1135C>T), p.Arg385Cys (c.1153C>T) and
p.Arg445Pro (c.1334G>C)) are, according to literature
(Balmer et al 2014), always associated with a variant clinical
course, defined as late onset and/or mild clinical and biochem-
ical phenotype. These 11 mutations as well as the two severe
mutations compile to a list of over 60 genotypes that are pro-
vided, together with the available clinical information, in Sup-
plemental Table 1. This list of 11 mutations comprises all
known base pair substitutions meeting the criteria of a variant
change (Table 1). The amino acid substitutions p.Ile100Thr
and p.Arg379Cys belong to the two most frequent changes in
ASLD that were initially described in Finish patients
(Linnebank et al 2002). Notably, the mutations c.1153C>T
(p.Arg385Cys) and c.1154G>T (p.Arg385Leu) affect the
same amino acid but are reported to result in variant and se-
vere clinical courses, respectively (Balmer et al 2014).
Construction of recombinant ASL mutations
Full-length ASL cDNA (1395 bp, RefSeq NM_000048.3) was
cloned into the expression vector pcDNA3 (Invitrogen, Carls-
bad, CA, USA) at BamHI and NotI restriction sites yielding
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pcDNA3-ASL-WT (P-WT) as described previously (Hu et al
2013). The mutant plasmids were constructed based on P-WT
by site-directed mutagenesis (Phusion Site-directed mutagen-
esis Kit, Finnzymes, Espoo, Finland) according to manufac-
turer’s protocol. Oligonucleotide primers designed to achieve
the respective point mutations are listed in Supplemental Ta-
ble 2. PCR-products obtained after mutagenesis were subject-
ed to BamHI (New England Biolabs, Beverly, MA, USA)
digestion and their size compared to P-WT by gel electropho-
resis. The PCR products with correct size were then trans-
formed into chemically competent DH5α™-T1® E.coli cells
(Invitrogen, Carlsbad, CA, USA) by using the heat shock
method and selected by growth on ampicillin-containing
(100 μg/ml) LB-agar. Screening-PCR with primers T7 for-
ward [5′TAATACGACTCACTATAGGG3′] and Sp6 reverse
[5′ATTTAGGTGACACTATAG3′] was used to identify posi-
tive clones. Then, mutant plasmids were isolated from E. coli
and purified by using standard procedures (QIAprep spin
column Miniprep Kit, Qiagen, Hombrechtikon, Switzerland).
The yielded mutant plasmids (P-mutant) were named as P-
R12Q, P-D31N, P-R95C, P-I100T, P-V178M, P-E189G, P-
R193W, P-Q286R, P-V335L, P-R379C, P-R385C, P-R385L
and P-R445P. All established constructs were confirmed by
sequencing using the BigDye Terminator cycle sequencing kit
V.1.1 (Applied Biosystems, ABI sequence).
Expression of ASL constructs in human embryonic kidney
293T cells
We have previously shown that 293 Tcells were an ideal ASL
expression system lacking endogenous ASL but allowing for
high ectopic ASL expression (Hu et al 2013). Cells were
grown, maintained and transiently transfected as described
before (Hu et al 2013). In brief, 293 T cells were grown in
Dulbecco’s modified Eagle’s medium+GlutaMAX (DMEM,
Gibco, Paisley, UK) supplemented with 10 % fetal bovine
Fig. 1 Mutations in the ASL protein mapped onto the secondary
structure of the human ASL protein sequence. Mutations are indicated
with red triangles. Helices are shown in light blue and beta strands are
shown as cyan arrows. Amino acids are coloured according to chemical
properties, with aspartic and glutamic acids are in red, arginines and
lysines in blue and aromatic amino acids are shown in green.
Secondary structure information was extracted from the known crystal
structures of ASL (PDB 1 K62) and figure was created with the program
CLCWorkbench. Sequence conservation information (presented in more
detail in Supplementary Fig. 1) is indicated below the amino acids used in
this study, H indicated high conservation and P indicates partial
conservation
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serum (FBS) and 1 % antibiotic/antimycotic solution (both
PAA, Pasching, Austria) and maintained in an incubator con-
taining 5 % CO2 at 37 °C in a humidified atmosphere. A total
of 7 μg of plasmid carrying ASL WT or the intended muta-
tions was introduced into the cells in a 60 mm-dish format,
using Lipofectamine™ LTX and PLUS™ Reagents
(Invitrogen, Basel, Switzerland) according to manufacturer’s
instructions. The empty vector (EV) pcDNA3 was used as
negative control.
Protein extraction and Western blot analysis
Cells were harvested 48 hours post-transfection and lysed in
Lubrol WX lysis buffer containing 0.15 % (w/v) of Lubrol
WX (Sigma Chemical Co., Poole, Dorset, UK) and 10 mM
of Tris–HCl (pH 8.6) for 1 hour on ice. Cell lysates were then
centrifuged at 16,873×g (14,000 rpm) at 4 °C for 15min using
Eppendorf microcentrifuge 5418. Protein concentrations in
the supernatants (cell extracts) were determined by Bradford
assay (Bradford 1976) using bovine serum albumin as
standard.
Western blotting was performed as previously described
(Laemmli 1970). Cell extracts (30 μg total protein) were sep-
arated by 10 % denaturing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and subse-
quently transferred to nitrocellulose transfer membranes
(Whatman GmbH, Dassel, Germany). The primary polyclonal
antibody anti-ASL (GeneTex, Irvine CA, USA), recognizing
























(mIU/mg) (% of WT) (% of WT) (mIU/mg) (mM) (% of WT) (°C)
WT WT – 1077.2±506.1 100 100±5.4 769.0±14.2 0.44±0.03 100 52.7±0.2
EV EV – 4.3±1.8 – 0.5±0.2 – – – –
c.35G>A p.R12Q variant 41.7±4.8 125 4.3±0.5 n.d. n.d. n.d. n.d.
c.91G>A p.D31N variant 20.1±2.2 88 2.0±0.7 n.d. n.d. n.d. n.d.
c.283C>T p.R95C variant 70.6±31.7 37 18.0±5.7 99.2f±2.7 0.18f±0.02 32 46.5f±0.1
c.299 T>C p.I100T variant 880.8±361.1 91 86.6±24.6 488.0f ±15.1 0.46±0.06 61 48.5f±0.1
c.532G>A p.V178M variant 644.1±246.3 73 88.9±19.2 714.0f±14.1 0.44±0.04 93 49.9f±0.2
c.566A>G p.E189G variant 1012.9±411.7 97 91.4±15.3 669.3f±16.1 0.49±0.05 78 48.1f±0.1
c.577C>T p.R193W variant 18.9±9.9 37 4.1±1.3 n.d. n.d. n.d. n.d.
c.857A>G p.Q286R severe 9.7±6.4 107 1.2±0.8 n.d. n.d. n.d. n.d.
c.1003G>Tp.V335L variant 553.8±135.3 104 46.4±21.0 443.6f±10.8 0.53±0.05 48 42.4f±0.5
c.1135C>T p.R379C variant 637.4±240.1 98 68.5±16.2 487.3f±9.0 0.25f±0.02 112 48.0f±0.1
c.1153C>T p.R385C variant 12.8±2.0 110 1.5±0.2 n.d. n.d. n.d. n.d.
c.1154G>Tp.R385L severe 10.3±3.3 99 1.3±0.4 n.d. n.d. n.d. n.d.
c.1334G>Cp.R445P variant 11.4±0.8 40 3.2±0.2 n.d. n.d. n.d. n.d.
EV, empty vector; WT, wild-type
aAll known genotypes to each missense mutation are published in (Balmer et al 2014) and are listed as well in Supplementary Table 1
bASL activities were measured under standard conditions using 13.6 mM argininosuccinate and given as experimental activity versus the total protein
content in the extract in mIU/mg protein
cASL protein content was given as percentage ofWT to estimate the expressed ASLmutant protein present in the extract compared to that ofWT based
on GAPDH by densitometry. It was determined by the following quotient: (ASL band for the mutant/GAPDH band for mutant)/(ASL band for WT/
GAPDH band for WT) using Western blot analysis
dThe specific activity of pure ASL given as percentage ofWTwas determined by the ratio of ASLmutant activity/ASLWTactivity/ASL protein content
indicating the relative enzyme activity of the expressed ASL mutant protein compared to that of the WT enzyme after normalization of the expressed
ASL protein levels based on GAPDH by densitometry estimation. This was determined in each transfection under the same conditions in triple
measurements from at least three independent transfection experiments, respectively
eVmax of pure ASL and Km values were calculated by Michaelis-Menten equation and the melting temperature Tm (resulted as V50 value on Prism) by
Boltzmann sigmoidal equation using GraphPad Prism 4 for curve fitting in triple measurements from the same experiment. Vmax values of pure ASL
were determined after normalization of the expressed ASL protein levels based on GAPDH by densitometry estimation using the same samples for
kinetics assay
f Significant difference compared with ASLWT (p<0.05)±S.D.: standard deviation; n.d.: not determined
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ASL residues 13 to 261 according to the manufacturer, was
used at a dilution of 1:1000 and the horseradish peroxidase
(HRP)-conjugated secondary antibody anti-rabbit (Santa Cruz
Biotechnology, Santa Cruz CA, USA) was used at a dilution
of 1:5000. Antibodies against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Santa Cruz Biotechnology) served
as loading control. ECL reagents (GE Healthcare, Glattbrugg,
Switzerland) were used for chemiluminescent labelling to de-
tect protein. To estimate expression levels of recombinant
ASL mutations, densitometry analysis of bands detected by
Western blotting was performed by using Carestream Molec-
ular Imaging software (Carestream Health, Germany).
ASL enzymatic activity assay, kinetic study and thermal
stability assay
The ASL enzymatic activity was determined spectrophoto-
metrically in cell extracts after three independent transient
transfections of P-WT or P-mutants, using a coupled assay
with arginase and measuring urea production as described
before (Engel et al 2012). In short, 100 μl of 34 mM
argininosuccinate (argininosuccinic acid disodium salt hy-
drate) in water and 100 μl arginase (50 units) (both Sigma-
Aldrich, Buchs, Switzerland) in 66.7 mM phosphate buffer
(11.1 mM potassium dihydrogenphosphate and 55.6 mM
disodium hydrogenphosphate, pH 7.5) were incubated at
37 °C for 5 min. Then 40 μl of cell extract (6 μg of total
protein diluted in albumin buffer yielding 0.15 mg/ml of con-
centration for WTand all mutations except for p.Arg95Cys, in
which we adapted protein quantity to 0.65 mg/ml according to
low expression levels) and 10 μl phosphate buffer were incu-
bated with the above reagents at 37 °C for 30 min. The reac-
tion was stopped by adding perchloric acid at a final concen-
tration of 2 %. In this assay, the measured extinctions are
corrected with the extinctions of a blank containing all the
reagents and cells as well as perchloric acid before the reaction
started. The ASL enzyme activities are given as mIU/mg total
protein indicating nmol of urea production/min/mg total pro-
tein and normalized according to the expressed ASL protein
levels by densitometry analysis using GAPDH as control. The
residual activities of ASL mutations are determined as per-
centage of ASLWT under the same conditions in triple mea-
surements, respectively.
Kinetic studies and thermal stability assays were performed
for ASL WT and mutations (p.Arg95Cys, p.Ile100Thr,
p.Val178Met, p.Glu189Gly, p.Val335Leu and p.Arg379Cys)
with residual ASL activities ≥18% of ASLWT. The measured
enzymatic activities were normalized according to the
expressed ASL protein levels by densitometry using GAPDH
as control. The kinetic parameters were determined by
Michaelis-Menten analysis at ten different argininosuccinate
concentrations after curve fitting using GraphPad Prism 4
(GraphPad Software, San Diego, CA, USA). For ASL thermal
stability assay all ASL proteins were diluted at 0.15 mg/ml in
albumin buffer (pH 7.4) and heated at different temperatures
for 30 min in a PCR machine, and then immediately cooled
down to 0 °C on ice followed by measuring ASL enzymatic
activity as above (incubation temperatures in °C for WT: 37,
42, 47, 52, 54, 56, 57; p.Arg95Cys: 37, 40, 43, 45, 47, 49, 51;
p.Ile100Thr, p.Glu189Gly and p.Val178Met: 37, 42, 47, 48.5,
50, 51.5, 53; p.Val335Leu: 37, 40, 42, 44, 46, 47, 48, 50;
mutant p.Arg379Cys: 37, 42, 47, 48, 48.5, 50, 51, 51.5, 53).
The mutant protein p.Arg95Cys, which is expressed less effi-
cient and exhibited only low enzyme activity, was diluted at
0.65 mg/ml. The melting temperature Tm (resulted as V50
value on Prism) indicating the temperature at which 50 % of
protein is inactivated, was determined by Boltzmann sigmoi-
dal curve fitting of the data using GraphPad Prism 4
(GraphPad Software). All assays were carried out in triplicate
using cell lysates from the same transfection experiment.
Structure models of ASL mutations
3D protein model and in-silico mutagenesis of ASL
The tetrameric 3D structure of ASL (NCBI NP_000039.2,
Uniprot P04424) sequence (AA 1–464) was built using the
in-silico mutagenesis of ASL structure (PDB 1 K62) as de-
scribed previously (Hu et al 2013). Structural mutagenesis
was performed with programs YASARA (Krieger et al
2004) and WHATIF (Vriend 1990). Side chains were opti-
mized by molecular dynamic (MD) simulations. The geome-
try information for the tetramer assembly was extracted from
the original crystallographic data. The final structure was re-
fined by a 1000 ps (MD) simulation using AMBER 2003
force field and checked with the programs WHAT_CHECK
(Hooft et al 1996), WHATIF (Vriend 1990), Verify3D (Bowie
et al 1991; Luthy et al 1992), and Ramachandran plot analysis
(Hooft et al 1997; Ramachandran et al 1963). Information
about the residues located at the argininosuccinic acid binding
pocket was extracted from the duck crystallin structure (PDB
1DCN) (Vallee et al 1999) using the program SiteEngines
(Shulman-Peleg et al 2004, 2005). Structures were depicted
with Pymol (www.pymol.org) and rendered as ray-traced im-
ages using the program POV-RAY (www.povray.org).
Structural properties of the proteins were calculated by
YASARA and WHATIF and general protein parameters
were calculated with Expasy protein tools (www.expasy.ch).
Molecular dynamics simulation for model refinement
The MD simulations were performed using AMBER03 force
field as described previously (Krieger et al 2004; Liu et al
2001). The simulation cell was filled with water, pH was fixed
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to 7.4 and the electrostatic potentials were evaluated for water
molecules in the simulation cell and adjusted by addition of
sodium and chloride ions. The finalMD simulations were then
run with AMBER03 force field at 298 K, 0.9 % NaCl and
pH 7.4 for 1000 ps to refine the models. The best models were
selected for analysis and evaluation of the effect of mutations
on monomer and tetramer structures. For the tetramer, muta-
tions were created on either one or all four subunits to analyze
different combinations of mutated and WTASL monomers.
Predicting the effect of mutations on protein stability using
site directed mutator (SDM)
The SDM tool (Topham et al 1997; Worth et al 2007) was
used for predicting the effect of mutations on ASL protein
stability. SDM software uses environment-specific substitu-
tion frequencies within homologous protein families to calcu-
late a stability score. The mutant structures used for analysis
were generated using the program ANDANTE (Smith et al
2007). SDM provides a pseudo delta G score for prediction of
protein stability.
RNA structure and stability prediction
RNA structure and stability prediction was performed using
the program RNAsnp (Sabarinathan et al 2013). A cutoff p
value of 0.2 was used for predicting the effect on RNA stabil-
ity. Both the global as well as local effects were evaluated for
predicting the changes in the RNA structure upon mutations.
The minimum free energy structures of the WT and mutant
RNA were used to display the secondary structures in the
graphic format.
Statistics
Statistical analyses were done using student one-tailed T-test
using the program GraphPad Prism 4 (GraphPad Software) to
describe the differences of Km and V50 values in kinetic and
thermal stability assays, respectively, betweenWTand mutant
ASLwith significant residual activities. Differences were con-
sidered as significant if the p value was <0.05.
Results
Expression of recombinant ASLWT and mutations in 293T
cells
In order to investigate the molecular characteristics of all
known naturally occurring ASL missense mutations associat-
ed with a variant clinical course in ASA patients (Balmer et al
2014), we first constructed the recombinant ASL WT and
mutant plasmids followed by introducing them into 293 T
cells, respectively. To check whether the recombinant diverse
ASL mutations can be expressed at the protein level, Western
blot analysis was performed under denaturing conditions
which yielded expression of all recombinant ASL mutant pro-
teins (Fig. 2a). More specific, a similar level of ASL expres-
sion as in WT was observed in all mutations except for
p.Arg95Cys, p.Arg193Trp and p.Arg445Pro with lower pro-
tein yields (37, 37 and 40 % of WT after normalisation with
loading control GAPDH by densitometry) (Table 1) indicating
that these mutations are less stable at either protein or RNA
level. We performed RNA secondary structure prediction to
check whether substantial variations from the WT RNAwere
the cause of lower expression levels. Our analysis showed
significant differences for the p.Arg193Trp (p-0.157) and
p.Arg445Pro (p-0.118) variants (Fig. 3). Thus, combination
of RNA and protein stability effects may be responsible for
lower expression of some mutant proteins.
Residual ASL enzymatic activities in transfected 293T cell
extracts
To determine whether the expressed ASL mutations have any
residual enzyme activity, we performed ASL enzyme activity
assays with the cell extracts used for Western blot analysis
(summary of data in Table 1 and Fig. 2b). The residual enzy-
matic activities were normalized according to the expressed
ASL protein levels by densitometry using GAPDH as control.
There was no relevant endogenous ASL activity in cells
transfected with EV. No significant residual activity (≤2 %
of ASL WT) was observed in cells respectively transfected
with two severe mutations p.Gln286Arg and p.Arg385Leu
as well as with two variant mutations p.Asp31Asn and
p.Arg385Cys, whereas cells expressing ASLWTyielded high
enzymatic activity (Fig. 2b). Cells expressing the other nine
variant mutations (p.Arg12Gln, p.Arg95Cys, p.Ile100Thr,
p.Val178Met, p.Glu189Gly, p.Arg193Trp, p.Val335Leu,
p.Arg379Cys and p.Arg445Pro) showed a residual activity
>3 % of ASL WT. Surprisingly, six of them (p.Arg95Cys,
p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu and
p.Arg379Cys) displayed a high level of ASL residual activity
≥16 % of ASLWT (Table 1 and Fig. 2b).
Kinetic study of variant mutations with high residual ASL
activities
Next, we wanted to study the molecular pathology in ASA
patients identified with variant mutations (p.Arg95Cys,
p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu and
p.Arg379Cys) harbouring residual activities ≥16 % of ASL
WT. Therefore, we analysed whether the kinetic parameters
were impaired in these mutations using different concentra-
tions of the substrate argininosuccinate (summary of data in
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Table 1 and Fig. 2c). The normalized maximal reaction veloc-
ity (Vmax) value in cells expressing recombinant mutant pro-
tein p.Arg95Cys showed about 13 % of that in cells express-
ing ASL WT, whereas the other five changes (p.Ile100Thr,
p.Val178Met, p.Glu189Glp, Val335Leu and p.Arg379Cys)
exhibited ≥58 % of Vmax of ASLWT. Moreover if compared
with WT, the Vmax values of mutations were consistent with
their residual activities and were all significantly lower
Fig. 2 Expression and enzymatic properties of the ASL WT and
mutations. a: Expression of recombinant WT and mutant ASL in 293 T
cells. These 293 T cells were transiently transfected with empty vector
pcDNA3 (EV), recombinant ASLWTand mutant plasmids, respectively.
ASL expression was detected by Western blot analysis using 30 μg of
total protein separated by 10 % SDS-PAGE. GAPDH (37 kDa) served as
loading control. b: Residual ASL activities of recombinant ASL proteins
in 293 T cells. ASL enzymatic activity was measured under standard
conditions using 13.6 mM argininosuccinate in cells transiently
transfected EV or diverse ASL constructs (6 μg of whole cell extracts),
respectively. The residual ASL activities are represented as a percentage
of ASL WT activity yielded under the same conditions and normalized
with GAPDH according to the expressed ASL protein levels by
densitometry. ASL severe mutations (Q286R and R385L) and EV
served as negative control and were marked in black. Nine variant
changes yielded residual activities >3 % of ASL WT (in red) were
marked in different colours: R95C in salmon, I100T in purple, V178M
in green, E189G in blue, V335L in cyan, R379C in orange, and R12Q,
R193W and R445P in grey. Two variant changes (D31N and R385C)
yielded no significant residual activities (≤2 % of WT) and were also
marked in black. All assays were carried out in triplicate measurements
of at least three independent experiments, respectively. c: Kinetic study of
recombinant ASL proteins showing significant residual activities. Kinetic
study was performed for ASLWTand six variant changes (R95C, I100T,
V178M, E189G, V335L, and R379C) (6 μg of whole cell extracts) with
≥18 % of WT activity using ten indicated different argininosuccinate
concentrations (ranging from 0.045 to 13.6 mM), respectively. The
measured enzymatic activities were normalized according to the
expressed ASL protein levels by densitometry using GAPDH as control
and represented as mIU/mg of whole cell extract. The kinetic parameters
Vmax given as relative value of 1 for ASLWT (referred to here as pure
enzyme according to the normalized expressed ASL enzyme) and Km in
mM of argininosuccinate were determined byMichaelis-Menten analysis
after curve fitting using GraphPad Prism 4. d: Thermal stability of
recombinant ASL proteins with high residual activities. A total of 6 μg of
protein diluted at 0.15 mg/ml (except for 26 μg of mutant R95C
protein, which is expressed less efficient and exhibited only low
enzyme activity and was therefore diluted at 0.65 mg/ml) in albumin
buffer was heated at the indicated temperatures for 30 min and
immediately cooled down on ice prior to ASL activity measurement.
ASL activity indicates in percentage of activity of respective protein
heated at 37 °C. The horizontal dashed line marks 50 % of ASL
activity, whereas the vertical dashed lines crossing the X-axis indicate
the temperatures (V50) at which 50 % of each protein is inactivated.
The value V50 (°C) was determined by Boltzmann sigmoidal analysis
after curve fitting using GraphPad Prism 4. All assays were carried out
in triplicate. Error bars indicate the standard deviation
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(p<0.05). Interestingly, Km values were not significantly
changed in p.Ile100Thr (0.46 mM), p.Val178Met
(0.44 mM), p.Glu189Gly (0.49 mM) and p.Val335Leu
(0.53 mM). In contrast, Km values were even slightly de-
creased in p.Arg95Cys (0.18 mM) and p.Arg379Cys
(0.25 mM) compared with that of ASLWT (0.44 mM) indi-
cating an increased substrate affinity in these two mutations.
Furthermore, the ratios of Vmax/Km in four changes
(p.Arg95Cys, p.Ile100Thr, p.Glu189Gly and p.Val335Leu)
were decreased (32 %, 61, 78 and 48 % of ASLWT, respec-
tively), while p.Val178Met and p.Arg379Cys showed similar
Vmax/Km ratios (93 and 112 %, respectively) compared to that
of WT indicating an unchanged catalytic efficiency in these
mutations.
Variant mutations with high residual ASL activities exhibit
thermal instability
In order to further investigate the molecular basis in variant
ASLmutations with significant residual activity, we measured
the thermal stability of mutant proteins by incubating the pro-
tein at different temperatures prior to activity determination
(summary of data in Table 1 and Fig. 2d). The Tm values,
indicating the temperatures at which 50 % of ASL activity is
lost, dropped to 46.5, 48.5, 49.9, 48.1, 42.4 and 48.0 °C for
p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly,
p.Val335Leu and p.Arg379Cys, respectively, compared with
ASLWT (52.7 °C). All V50 values of mutations were signif-
icantly decreased (p<0.05) suggesting thermal instability of
these ASL variants.
Interpretation of the effects of the ASL mutations on the basis
of ASL structure
We analysed the effect of mutated residues in human ASL by
in-silico mutagenesis of known x-ray crystal structures of
ASL protein as template. We also compared human, horse,
cow, cat, pig, chimpanzee, dog and rat ASL protein sequences,
and amino acids near the substrate binding site and interaction
points of the tetrameric protein complex were checked for
conservation (Supplementary Fig. 1). Amino acids involved
in substrate access and catalysis were conserved across spe-
cies and no structurally significant substitutions were ob-
served in any of the sequences analysed (Supplementary
Fig. 1). A high resolution x-ray crystal structure of ASL that
describes the conformations and topologies of ASL mono-
mers has been described by Sampaleanu et al (Sampaleanu
et al 2001) which formed the basis of our structural analysis.
The enzymatically active form of ASL is a homotetramer
which is formed by four identical monomer units which have
three distinct helix rich subdomains (Fig. 4) (Sampaleanu et al
2001).
The location of ASLmutations studied in this report on one
subunit is depicted in Fig. 4. We performed in-silico mutagen-
esis on the crystal structure of ASL to generate models of 13
ASL mutations (Supplemental Figs. 2–5) in which amino
acids were mutated and side-chains of mutated residues were
optimized by MD simulations. Each refined structure was
evaluated for a variety of structural parameters like breaking
of salt-bridges and hydrogen bonds, changes in charge, size
and volume of the altered amino acid and interaction with
neighbouring residues, to evaluate the impact of mutations
as described previously for several other proteins and struc-
tures (Flück et al 2009; Pandey et al 2007; Pandey and Mullis
2011). A detailed description of the predicted properties of the
ASL mutations is provided in the Supplementary material and
is only summarized in the following.
The arginine 12 residue is located on the highly flexible N-
terminus loop in the ASL and showed hydrogen bonding net-
works with several residues on different ASL subunits. Dis-
tortions in the N-terminus loop caused by the mutation of
arginine 12 may lead to disruption of ASL substrate binding
leading to a loss of activity. This mutation has been reported to
cause a milder form of disease but showed only 4.3 % of WT
activity in our assays and Km/Vmax values could not be accu-
rately determined due to low activity. The aspartate 31 residue
is part of the access channel in ASL and had severe loss of
activity in our assays. Patients harbouring aspartate to aspara-
gine mutation showed late onset ASL deficiency and mental
retardation. The arginine 95 residue has a role in structural
stability of ASL and its mutation to cysteine leads to an un-
stable protein as observed in our experiments. Interestingly
the Km values were lower suggesting a wider substrate access
site but loss of stability also led to greatly lower Vmax values
Fig. 3 A comparison of theWTandmutant RNA secondary structures of
the R193W and R445P variants. The minimum free energy structure of
theWTandmutant RNAwere used to provide graphical representation of
the secondary structures. The wild-type RNA is shown in green
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affecting the overall activity of this variant, but sufficient re-
sidual activity would be consistent with a milder form of dis-
ease. The isoleucine 100 residue was not found to have any
direct role in substrate binding or catalysis and its mutation to
threonine did not influence Km but had ∼40 loss of activity.
The valine 178 residue is part of the central helix bundle
forming the core ASL structure but its mutation to methionine
did not have any significant effect on ASL activity as per its
clinical phenotype of a milder form of ASLD. Several other
residues located nearby on the core helix bundle interact via
salt-bridge formations and compensate for the structural insta-
bility that may arise due to mutation. The glutamate 189 and
arginine 193 are involved in structural stability of the central
helix bundle of the ASL tetramer. We found that loss of glu-
tamate interaction with arginine 193 of an adjacent ASL sub-
unit was compensated by strong ionic interactions between
glutamate 185 and arginine 193 on opposing ASL subunits.
Mutation of glutamine to glycine had only a mild effect on
Vmax and Km values were unchanged which is consistent with
a mild clinical phenotype. However, mutation of arginine 193
was found to cause disruption of the core structure of ASL
tetramer due to loss of salt bridges with glutamate 185 and 189
on opposing ASL subunits. The arginine 193 to tryptophan
mutant had severe loss of activity and Km/Vmax values could
not be determined accurately due to low activity. The gluta-
mine 286 residue has been studied before and shows severe
loss of activity due to disruption of substrate binding site. The
valine 335 residue is involved in multiple hydrophobic inter-
actions and contributes to the overall protein stability. The
valine 335 mutation to leucine had no impact on substrate
binding as expected but had somewhat lower Vmax values
which would indicate structural instability as confirmed by
thermal stability assays. The arginine 379 has a role in the
structural stability of ASL monomer. The mutation of arginine
379 to cysteine showed lower Km for the substrate which
could be due to a more flexible active site due to structural
instability but Vmax values were lower than the WT enzyme
resulting in overall similar enzyme efficiency (Vmax/Km). The
arginine 385 residue stabilizes the carboxy terminal helix of
ASL monomer and its mutations resulted in severe loss of
activity. The arginine 385 mutation to cysteine has been re-
ported to cause a milder phenotype but our kinetic and com-
putational analysis could not explain this phenotype. The ar-
ginine 445 residue stabilizes the c-terminus helix of the ASL
Fig. 4 Three dimensional structure of ASL tetramer showing overall
structure of ASL tetramer and the location of mutations on one subunit.
Monomeric structure ofWTASL has three distinct subdomains. Domains
1 and 3 have similar structure and topology with two helix-turn-helix
motifs in perpendicular arrangement. Domain 2 has nine helices and five
of them form the central five helix bundle with up-down-up-down-
up topology. In the ASL homotetramer, active site residues are
contributed by three different subunits. ASL structure is shown as a
ribbons model with different subunits coloured in rainbow, cyan,
magenta and yellow. The rainbow and cyan subunits form a dimer and
join with another dimer formed by magenta and yellow subunits to form
the tetramer. Active site residues from one of the sites are shown as solid
surfaces while catalytic centre (H160) is shown as spheres. For clarity,
helices and sheets are only shown for one subunit shown in rainbow
colours violet at N-terminus and red at C-terminus. The mutations
studied in this report are shown as ball and stick models. Each active
site is formed by residues from three different monomeric subunits,
with contributions from three conserved sequences coming from a
different subunit. The histidine 160 residues at the catalytic centres are
shown for each subunit
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monomer and its mutation to proline disrupts interactions with
aspartate 152 and glutamate 435 causing structural instability.
This mutation showed severe loss of activity and kinetic pa-
rameters could not be determined.
In the SDM analysis, where an arbitrarily chosen cut-off of
2 kcal mol−1was used for predicting a disease causing effect, a
negative score is indicative of a destabilizing effect while a
positive score suggests a stabilizing effect. Using this tool, the
p.Ile100Thr, p.Glu189Gly and p.Arg445Pro mutations in
ASL were predicted to decrease the structural stability and
cause disease (Table 2). Structural stability of the tetramer
interface is also crucial for the complex formation which
was analysed in detail by looking at ionic interactions and
hydrogen bond network of residues at the interface of central
helices in tetrameric structure (Supplementary Table 3).
Discussion
The broad clinical and biochemical variability of ASLD has
been the subject of various investigations over recent years.
The presence of residual enzyme activities was confirmed in
different expression systems (Barbosa et al 1991; Engel et al
2012; Hu et al 2013; Sampaleanu et al 2001; Trevisson et al
2009; Walker et al 1990, 1997; Yu et al 2001) and was con-
sidered as a factor contributing to the spectrum of disease. On
the other hand, the finding of cognitive impairment despite
higher ASL activity (Ficicioglu et al 2009) and, in other
patients, of normal outcome despite undetectable ASL activ-
ities (Mercimek-Mahmutoglu et al 2010) led to the assump-
tion of Bno correlation between enzyme activity and neuro-
clinical outcome^ (Erez et al 2011a). This overall inconsistent
situation may in part be explained by the variety of methods
employed including different enzymatic measurements, direct
(Ficicioglu et al 2009; Tomlinson andWestall 1964) as well as
indirect (Jacoby et al 1972; Kleijer et al 2002) assays, and
likewise different ways of expression, yielding recombinant
purified ASL protein from prokaryotic overexpression (Engel
et al 2012) as well as eukaryotic systems using yeast
(Trevisson et al 2009) or human embryonic kidney 293 T cell
lysates (Hu et al 2013).
Here, we exploited our recently established eukaryotic ex-
pression system that is based on crude cell extracts of
transfected 293 T cells (Hu et al 2013) to study in detail all
known variant ASL mutations (Balmer et al 2014). The stud-
ied 11 variant and two severe missense mutations represent a
substantial proportion of the total 92 known ASL missense
mutations of which 25 are known to be associated with a
severe phenotype (Balmer et al 2014).
Validating our expression system, we found high levels of
ASL enzyme activity in the recombinant WT and levels<
1.5 % ofWT in the severe mutations and sufficient expression
of all recombinant proteins (Fig. 2a). Interestingly, while most
mutations, including the severe changes p.Gln286Arg and
p.Arg385Leu, expressed at levels comparable to ASL WT,
we found three variant mutations that yielded clearly lower
protein expression (p.Arg95Cys, p.Arg193Trp, p.Arg445Pro)
indicating their disease causing role and already pointing to-
wards instability of the mutant proteins. The RNA secondary
structure may also play a role in lower levels of expression.
Therefore, a combination of lower translation as well as pro-
tein instability may affect the overall outcome of some ASL
variants.
S ix (p .Arg95Cys , p . I l e100Thr, p .Val178Met ,
p.Glu189Gly, p.Val335Leu and p.Arg379Cys) of the 11 vari-
ant ASL constructs yielded levels of residual activity ≥18% of
WT (Table 1 and Fig. 2b). Two of these mutations,
p.Val178Met and p.Val335Leu, displayed relevant enzyme
activities already in yeast expression (Trevisson et al 2009)
as well as in the case of p.Val178Met in [14C]citrulline incor-
poration studies (Kleijer et al 2002). Four of the mutant ASL
proteins (p.Ile100Thr, p.Val178Met, p.Glu189Gly and
p.Val335Leu) showed no significant changed Km values and
two mutations (p.Arg95Cys and p.Arg379Cys) even
displayed slightly decreased Km values (Table 1), which
would explain their milder phenotype. This is in contrast to
significantly lowered Km values obtained in bacterial expres-
sion of p.Val178Met and p.Arg379Cys (Engel et al 2012).
Four of the mutant ASL proteins (p.R95C, p.Ile100Thr,
p.Glu189Gly and p.Val335Leu) showed decreased enzyme
efficiency (Vmax/Km: 32, 61, 78 and 48 % of ASL WT,
Table 2 Prediction of protein stability using SDM














Prediction of structural changes were done based on statistical potential
energy calculation (Worth et al 2007). In the SDM analysis a negative
score is indicative of a destabilizing effect and positive score suggests a
stabilizing effect. A cut-off of 2 kcal mol−1 was used for predicting a
destabilizing effect (in bold). L: loop; H: helix; T: turn
None of themutations led to the prediction of a gross change in secondary
structure of the element where the mutated residue belongs
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respectively) possibly contributing to the clinical phenotype
despite surprisingly high residual activities. For the majority
of the mutants studied here, the clinical phenotype, which is at
least known for each one or few patients (as summarized in
(Balmer et al 2014)), is in accordance with the relevant levels
of ASL activity. Exceptions to this comprise the following
mutants: mutation p.Arg12Gln would be expected to be asso-
ciated with rather high levels of ASL activity based on a single
report of an asymptomatic individual with the p.Arg12Gln/
p.Glu36Glyfs*32 genotype (Balmer et al 2014) but was found
with only 4 % of ASL-WT activity. For p.Asp31Asn, there is
only information from two patients with late onset ASLD
resulting in mental retardation (Trevisson et al 2007) but the
data from our expression system for this mutant would rather
predict a more severe course. In mutations pArg385Cys and
p.Arg445Pro, we consider the residual ASL activity levels as
consistent with the available clinical information, which indi-
cate rather severe disease (albeit not always classical neonatal
onset) in patients homozygous for p.Arg385Cys while there is
only information from one patient available with p.Arg445Pro
(Dursun et al 2008). These discrepancies indicate that, al-
though in general a reliable tool, our assay fails to represent
in some cases the actual activity in the patient.
In a previous study applying ASL expression in yeast, mu-
tations p.Val178Met and p.Val335Leu were shown by immu-
noblot analysis to encode for stable proteins (Trevisson et al
2009) and this is confirmed here for most of the variant mu-
tations (Fig. 2a). However in silico modelling of p.Arg95Cys,
p.Ile100Thr, p.Glu189Gly, p.Val335Leu and p.Arg379Cys,
Q286R and R445P suggested either ASL protein or tetramer
instability. The findings of a low expression level for
p.Arg95Cys, p.Arg193Trp and p.Arg445Pro, as well as de-
creased thermal stability for p.Arg95Cys, p.Ile100Thr,
p.Glu189Gly, p.Val335Leu and p.Arg379Cys further point
towards an unstable ASL protein in the aforementioned mu-
tations. This opens the possibility of stabilizing these mutant
proteins by pharmacological chaperones as a new therapeutic
approach in ASLD. In studies investigating this, the impact of
intragenic complementation (Walker et al 1997; Yu et al 2001)
on the efficacy of pharmacological chaperones is difficult to
foresee but should not prevent such further work. Since all of
the mutations that possibly qualify for chaperone treatment are
recurrent and some even belong to the most frequently found
mutations in ASLD patients (Balmer et al 2014), identification
of compounds that can be used for this purpose should be-
come a research priority. This is underlined by the fact that
about 30 % (n=49) of the 160 known different genotypes are
affected at least on one allele by any of the mutations de-
scribed here as possible targets of chaperone treatment.
Our findings are further substantiated by predictions from
structure modelling (Supplementary material). The variants
studied in this report can be divided in two different groups
based on their impact on the structure of the ASL protein.
Most of the variants affect the atomic interactions within a
monomeric ASL unit while variants p.Glu189Gly and
p.Arg193Trp were found to impact the tetramer formation.
The enzyme kinetic data and thermal stability analysis were
in general agreement with the structural analysis. Mutations
with complete or near-complete effects on activity were either
near the active site (p.Arg12Gln, p.Asp31Asn, p.Gln286Arg,
p.Arg385Cys and p.Arg385Leu) or hampered the structural
s tabi l i ty of monomer (p.Arg445Pro) or tet ramer
(p.Arg193Trp). Two variants near the tetrameric interface,
p.Val178Met and p.Glu189Gly did not have severe effects
on enzymatic activity. Further computational analysis showed
that multiple strong ionic interactions between arginine 193,
lysine 192 of one subunit with the glutamate 185 and gluta-
mate 189 of another interacting ASL monomeric unit could
compensate for loss of some interactions. The major result of
this analysis is the role of arginine 193 in the structural stabil-
ity of the ASL complex. Involvement of arginine 193 with
several adjacent acidic residues meant that any mutation of
arginine 193 residue would have a strong negative impact on
protein stability and catalytic activity.
In conclusion, we have found significant residual levels of
ASL activity in some of the mutations that are associated with
a variant clinical and biochemical phenotype of ASLD. Like-
wise, this study provides evidence for instability of the mutant
proteins and adds ASLD to the list of target diseases for novel
therapeutic approaches with small molecules allowing scaf-
folding to improve stability. Based on recent data on the ge-
notypes found in ASLD it is obvious that the search for com-
pounds that stabilize the ASL protein should be pursued with
highest priority to eventually gain benefit for a substantial
proportion (about 30 %) of ASLD patients.
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